Dr. Moskowitz on the ALCANZA Trial in CTCL
4 Pogledi
• 08/09/23
0
0
Ugraditi
administrator
Pretplatnici
Alison J. Moskowitz, MD, clinical director, Lymphoma Inpatient Unit, Memorial Sloan Kettering Cancer Center, discusses the data that led to the approval of brentuximab vedotin (Adcetris) in patients with cutaneous T-cell lymphoma (CTCL).
Prikaži više
Komentari na Facebooku
SORT BY-
Najbolji komentari
-
Najnoviji komentari